Array BioPharma Inc. ARRY was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $16.82 to $19.20 in the past one-month time frame.
The move came after the company reported better-than-expected second-quarter fiscal 2019 results (ended Dec 31, 2018).
The company has seen a mixed track record when it comes to estimate revisions of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Array BioPharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Array BioPharma Inc. Price
Array BioPharma Inc. Price | Array BioPharma Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Acorda Therapeutics, Inc. ACOR , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is ARRY going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Array BioPharma Inc. (ARRY): Get Free Report Acorda Therapeutics, Inc. (ACOR): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research